Lilly vs Novo: Weight Loss Drug Race
- Being second to market can still yield ample rewards, as Eli Lilly is demonstrating with its weight-loss drug, Zepbound.
- The success of Zepbound, a new weight loss drug, has impacted Novo Nordisk.
- The competition between Eli Lilly and novo Nordisk in the weight loss market is expected to intensify, with both companies vying for market share and exploring new formulations...
Eli Lilly’s Zepbound is making serious waves, racking up $4.9 billion in revenue,despite entering the weight loss drug race after Novo Nordisk’s Wegovy. This surge substantially impacts Novo Nordisk, forcing them to revise their 2025 sales forecasts. The competitive landscape is shifting rapidly, with Lilly’s stock price soaring, while their competitor’s dips. News Directory 3 has the breaking details on this evolving market. Investors and patients alike are watching the battle for dominance in this lucrative pharmaceutical sector. Discover what’s next as these two pharmaceutical giants continue to innovate and compete for market share.
Eli Lilly’s Zepbound Gains Traction in Weight Loss Market
Being second to market can still yield ample rewards, as Eli Lilly is demonstrating with its weight-loss drug, Zepbound. Despite being approved in the U.S. in November 2023, more than two years after Novo nordisk’s Wegovy, Zepbound generated $4.9 billion in revenue in its first year. This figure is more than half of Wegovy’s $8.2 billion over the same period.
The success of Zepbound, a new weight loss drug, has impacted Novo Nordisk. On May 7, the Danish company revised its sales forecast for 2025, citing slower growth than anticipated in the weight-loss drug sector. Since the beginning of 2024, Novo Nordisk’s share price has decreased by a third, while Lilly’s has seen a comparable increase.
What’s next
The competition between Eli Lilly and novo Nordisk in the weight loss market is expected to intensify, with both companies vying for market share and exploring new formulations and delivery methods.